Nautilus Biotechnology (NAUT) investor relations material

Company overview and business model

• Development stage life sciences company focused on proteomics platform technology using Iterative Mapping for single-molecule protein analysis at scale.

• Mission is to broaden access to high-quality proteomic data and support advancements in human health and medicine.

• Nautilus Voyager™ platform integrates nanofabricated protein arrays, affinity reagent probing, advanced optics, fluidics, and machine learning-based analysis.

• Incorporated in Delaware after a business combination and domestication from a Cayman Islands entity in 2021.

Financial performance and metrics

• Net tangible book value as of June 30, 2026 was $131.1 million, or $1.03 per share.

• After the offering, as adjusted net tangible book value would be $251.8 million, or $1.05 per share, resulting in immediate dilution of $0.07 per share to new investors.

• Company has experienced net operating losses and negative cash flows from operations, as noted by its independent auditor.

Use of proceeds and capital allocation

• Net proceeds from the offering are intended for general corporate purposes and working capital, including continued product development, research and development, and commercialization of the proteomics platform.

• Management retains broad discretion over allocation and timing of expenditures.

• Pending use, proceeds will be invested in interest-bearing, investment-grade securities, certificates of deposit, or government securities.